These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35293692)

  • 61. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
    Chen M; Xu Y; Zhao J; Li J; Liu X; Zhong W; Wang M
    Thorac Cancer; 2021 Sep; 12(17):2339-2344. PubMed ID: 34291566
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples.
    Ambrosini-Spaltro A; Dubini A; Pieri F; Ravaglia C; Delmonte A; Poletti V
    Diagn Cytopathol; 2021 Feb; 49(2):303-310. PubMed ID: 33091231
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
    Xu H; Dong X; Zhao H; Hou T; Chen C; Chen G; Ye J; Li Y
    J Clin Lab Anal; 2021 Mar; 35(3):e23696. PubMed ID: 33434308
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods.
    Lloyd IE; Zhou W; Witt BL; Chadwick BE
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):107-113. PubMed ID: 29084060
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunocytochemistry for predictive biomarker testing in lung cancer cytology.
    Jain D; Nambirajan A; Borczuk A; Chen G; Minami Y; Moreira AL; Motoi N; Papotti M; Rekhtman N; Russell PA; Savic Prince S; Yatabe Y; Bubendorf L;
    Cancer Cytopathol; 2019 May; 127(5):325-339. PubMed ID: 31050216
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
    Dolled-Filhart M; Locke D; Murphy T; Lynch F; Yearley JH; Frisman D; Pierce R; Weiner R; Wu D; Emancipator K
    Arch Pathol Lab Med; 2016 Nov; 140(11):1259-1266. PubMed ID: 27788043
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
    Lin YY; Lin LY; Hang JF; Lin CH; Ho HL; Chou TY
    Cancer Cytopathol; 2021 Feb; 129(2):148-155. PubMed ID: 32976705
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms.
    Matsumoto K; Ohara T; Fujisawa M; Takaki A; Takahara M; Kato H; Yoshida R; Umeda Y; Yagi T; Matsukawa A; Okada H
    J Gastrointest Surg; 2022 Jun; 26(6):1213-1223. PubMed ID: 35137343
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2021 May; 21(5):445-454. PubMed ID: 33896308
    [No Abstract]   [Full Text] [Related]  

  • 80. [Predictive immunocytochemistry in non-small cell lung carcinoma].
    Brcic L; Savic Prince S
    Pathologe; 2022 May; 43(3):222-228. PubMed ID: 35403870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.